462068-57-1

Basic information

• Product Name: (4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID
• Synonyms: TIMTEC-BB SBB007027;(4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID;AKOS B007037;CHEMBRDG-BB 4004449;ART-CHEM-BB B007037;BENZENEACETIC ACID, 4-(1H-TETRAZOL-1-YL)-;Albb-005537;[4-(1H-tetrazol-1-yl)phenyl]acetic acid(SALTDATA: FREE)
• CAS NO: 462068-57-1
• Molecular Formula: C₉H₈N₄O₂
• Molecular Weight: 204.19
• Mol File: 462068-57-1.mol

Chemical Properties

• Boiling Point: 433.2°C at 760 mmHg
• Flash Point: 215.8°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 2.84E-08mmHg at 25°C
• Refractive Index: 1.694
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID(462068-57-1)
• EPA Substance Registry System: (4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID(462068-57-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 462068-57-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
(4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID is used as a starting material or intermediate in the synthesis of various pharmaceutical drugs. Its tetrazole ring and phenylacetic acid structure contribute to its potential therapeutic properties, making it a valuable component in drug discovery and development processes.
Used in Anti-inflammatory Applications:
(4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID is used as an anti-inflammatory agent for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its tetrazole ring may contribute to its anti-inflammatory effects, offering a new avenue for the treatment of various inflammatory diseases.
Used in Analgesic Applications:
(4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID is used as an analgesic agent to relieve pain and discomfort. Its potential pain-relieving properties make it a candidate for the development of new pain management therapies, providing an alternative to existing analgesics.
Used in Research and Development:
(4-TETRAZOL-1-YL-PHENYL)-ACETIC ACID is used as a research compound to explore its pharmacological properties and potential applications in various therapeutic areas. Its unique structure and biological activities make it an interesting target for further investigation, with the aim of uncovering new uses and expanding its potential applications in medicine.

InChI:InChI=1/C9H8N4O2/c14-9(15)5-7-1-3-8(4-2-7)13-6-10-11-12-13/h1-4,6H,5H2,(H,14,15)

Upstream product

• 1197-55-3 4-aminophenylacetic acid 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 1428477-81-9 4-bromo-5-[2-(1-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}piperidin-4-yl)ethyl]-2-benzofuran-1(3H)-one 
• 1428477-82-0 4-bromo-5-[(Z)-2-(1-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}piperidin-4-yl)ethynyl]-2-benzofuran-1(3H)-one 
• 1428478-52-7 1-{4-hydroxy-4-[(trimethylsilyl)ethynyl]piperidin-1-yl}-2-[4-(1H-tetrazol-1-yl)phenyl]ethanone 
• 1428477-26-2 1-{4-[(E)-2-(2,1,3-benzoxadiazol-5-yl)ethenyl]piperidin-1-yl}-2-[4-((1H)-tetrazol-1-yl)phenyl]ethanone 
• 1616594-70-7 6-[(3R,9aS)-8-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}octahydropyrazino[2,1-c][1,4]oxazin-3-yl]-3,4-dihydro-1H-isochromen-1-one 
• 1428479-68-8 5-[(3-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}-3-azabicyclo[3.1.0]hex-6-yl)ethynyl]-2-benzofuran-1(3H)-one 
• 1374569-51-3 5-(2-(4-(2-(4-(1H-tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one 
• 1616595-59-5 4-methyl-5-[(3S,9aS)-8-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}octahydropyrazino[2,1-c][1,4] oxazin-3-yl]-2-benzofuran-1(3H)-one 
• 1616594-56-9 4-methyl-5-[(3R,9aS)-8-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}octahydropyrazino[2,1-c][1,4] oxazin-3-yl]-2-benzofuran-1(3H)-one 
• 1428478-62-9 1-[6-(hydroxymethyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-[4-(1H-tetrazol-1-yl)phenyl] ethanone 
• 1428477-87-5 6-[2-(1-{[4-(1H-tetrazol-1-yl)phenyl]acetyl}piperidin-4-yl)ethyl]-3,4-dihydro-1H-isochromen-1-one 
• 1428477-33-1 1-{4-[(4-nitrophenyl)sulfanyl]piperidin-1-yl}-2-[4-(1H-tetrazol-1-yl)phenyl]ethanone 
• 1428478-61-8 1-(6-ethynyl-3-azabicyclo[3.1.0]hex-3-yl)-2-[4-(1H-tetrazol-1-yl)phenyl]ethanone 
• 1428479-73-5 1-{4-[2-(3-cyano-4-fluorophenyl)ethyl]-4-(amino)piperidin-1-yl}-2-[4-(1H-tetrazol-1-yl)phenyl]ethanone 

Relevant articles and documents

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

Building heterocyclic systems with RC(OR)2+ carbocations in recyclable bronsted acidic ionic liquids: Facile synthesis of 1-substituted 1H-1,2,3,4-tetrazoles, benzazoles and other ring systems with CH(OEt)3 and EtC(OEt)3 in [EtNH 3][NO3] and [PMIM(SO3H)][OTf]

1-Aryl/alkyl-1H-1,2,3,4-tetrazoles can conveniently be synthesized in one-pot reactions from the corresponding amines by reaction with TMSN 3 and CH(OEt)3 using the readily available, recyclable, Bronsted acidic ionic liquids [EtNH3][NO3] IL-1 and [PMIM(SO3H)][OTf] IL-2 under mild conditions in high yields. Based on comparative reactions, whereas both ILs are excellent promoters, reactions are completed with shorter reaction times and in higher yields with IL-2. Among 24 examples provided, identical products were obtained via the two ILs, except in the case of 2-aminobenzoic acid where tetrazole was formed with IL-2 and 2-ethylquinazolin-4(3H)-one was formed with IL-1. By leaving out TMS-N 3 from the reaction, the in-situ formed CH(OEt)2 + and EtC(OEt)2+ (via their corresponding orthoesters) react under sonication with o-phenylenediamine bearing various substituents, o-aminothiophenol and o-aminophenol to form a wide array of benzazoles (benzimidazole, benzothiazole and benzoxazole) and quinazolin-4(3H)-one in high yields (18 examples). The two ILs reacted differently in reaction with 2-aminobenzamide, whereas quinazolin-4(3H)one was formed with IL-2/CH(OEt)3, the "unexpected" N-ethylquinazolin-4(3H)one was isolated with IL-1/CH(OEt)3. The latter was also formed from 2-aminobenzoic acid in IL-1/CH(OEt)3. Mechanistic implications are addressed. The reported protocols enable rapid assembly of a host of heterocyclic systems in high yields with the added advantage of recycling and re-use of the ILs.